RT info:eu-repo/semantics/article
T1 Host centric drug repurposing for viral diseases
A1 de Siqueira Santos, Suzana
A1 Yang, Haixuan
A1 Galeano Alfonso, Aldo Javier
A1 Paccanaro, Alberto
A2 Centro de Ingeniería para la InvestigaciónDesarrollo e Innovación Tecnológica
AB Computational approaches for drug repurposing for viral diseases have mainly focused on a small number of antivirals that directly target pathogens (virus centric therapies). In this work, we combine ideas from collaborative filtering and network medicine for making predictions on a much larger set of drugs that could be repurposed for host centric therapies, that are aimed at interfering with host cell factors required by a pathogen. Our idea is to create matrices quantifying the perturbation that drugs and viruses induce on human protein interaction networks. Then, we decompose these matrices to learn embeddings of drugs, viruses, and proteins in a low dimensional space. Predictions of host-centric antivirals are obtained by taking the dot product between the corresponding drug and virus representations. Our approach is general and can be applied systematically to any compound with known targets and any virus whose host proteins are known. We show that our predictions have high accuracy and that the embeddings contain meaningful biological information that may provide insights into the underlying biology of viral infections. Our approach can integrate different types of information, does not rely on known drug-virus associations and can be applied to new viral diseases and drugs.
PB Public Library of Science
YR 2025
FD 2025-04-02
LK http://hdl.handle.net/20.500.14066/4733
UL http://hdl.handle.net/20.500.14066/4733
LA eng
NO de Siqueira Santos, S., Yang, H., Galeano, A., & Paccanaro, A. (2025). Host centric drug repurposing for viral diseases. PLoS Computational Biology, 21(4), Artículo e1012876. https://doi.org/10.1371/journal.pcbi.1012876
NO Correspondencia: alberto.paccanaro@rhul.ac.uk.
NO Consejo Nacional de Ciencia y Tecnología
DS MINDS@UW
RD 03-sep-2026